• Discover the latest ESC guidance on heart failure, and the first-ever ESC guidance on cardiovascular disease and chronic kidney disease.
• Explore new evidence on prevention across the life course, including statin therapy and sustained blood-pressure control to reduce cardiovascular risk.
• Learn about trials into potential of transcatheter treatment for severe tricuspid regurgitation, and aficamten for symptomatic non-obstructive hypertrophic cardiomyopathy, and much more.

Speakers

Dr Sarah Birkhoelzer, Heart Failure and Imaging Fellow, University Hospitals Dorset
Dr Patrick Hurley, Cardiology Registrar, University Hospitals Dorset

• Explore the implications of this new, broad and holistic framework  

• Understand that early and pro-active diagnosis is a key factor 

• Discover the 12 key priorities outlined in the guidelines 

• Learn the new ABCDE Approach 

Speakers

Beverley Bostock RN MSc MA Queen’s Nurse  President-Elect Primary Care Cardiovascular Society  

Professor Raj Thakkar BSc(Hons) MBBS MRCGP MRCP(UK)FRCP(Edin) President, Primary Care Cardiovascular Society, UK 

• Early detection and accurate diagnosis are essential for optimising clinical management and improving outcomes in patients with amyloidosis
• The National Amyloidosis Centre has a range of advanced diagnostic techniques to confirm the presence of amyloidosis in a person
• Investigations may include SAP scintigraphy, cardiac MRI scans, DPD scans and genetic testing
• Accurate subtyping enables tailored therapeutic strategies, which are key to effective disease management

Speakers

Emily Dixon, Principal Genetic Counsellor
Darren Foard, Lead AL Amyloidosis Clinical Nurse Specialist
Professor Philip Hawkins, Consultant Physician; Clinical Director; Founder of NAC
David Hutt, Lead Nuclear Medicine Technologist
Dr Ana Martinez Naharro, Consultant Cardiologist
Dr Tamer Rezk, Consultant Nephrologist
Dr Dorota Rowczenio, Head of Genetic Service
Angelique Smit, Lead Clinical and Research Nurse

• Early detection and diagnosis are key for improving outcomes in people with amyloidosis
• There are 3 major types of amyloidosis seen at the NAC, each requiring specialised treatment
• The NAC processes over 2500 cases of amyloidosis per year and offers a holistic approach to managing amyloidosis, including genetic counselling

Speakers

Christine Chiti, Clinical TTR Nurse Specialist
Emily Dixon, Principal Genetic Counsellor
Professor Marianna Fontana, Deputy Clinical and Research Lead
Janet Gilbertson, Head of Histology; Proteomic Service and Laboratory Manager
Professor Julian Gillmore, NAC Research Lead
Professor Philip Hawkins, Consultant Physician; Clinical Director; Founder of NAC
Dr Yousuf Razvi, Clinical Research Fellow
Angelique Smit, Lead Clinical and Research Nurse
Dr Tamer Rezk, Consultant Nephrologist
Professor Ashu Wechalekar, Laboratory Director and Consultant Haematologist
Dr Carol Whelan, Consultant Cardiologist

Speakers:

Professor Julian Gillmore, Centre Head, Centre for Amyloidosis, University College London, The National Amyloidosis Centre, London

Dr Tamer Rezk, Academic Consultant Nephrologist, University College London, London

View the BJC Amyloidosis Hub

A guide for all members of the cardiovascular and primary care teams on what to look for, and what to do if you suspect amyloidosis: signs and symptoms, diagnostic tests and studies, and the treatment options currently available.

Speakers:

Dr Sarah Birkhoelzer, Heart Failure and Imaging Fellow, University Hospitals Dorset NHS Foundation Trust, Bournemouth

View the BJC Amyloidosis Hub

Featuring

Professor John McMurray, Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health
Professor Richard Hobbs, Mercian Professor of Primary Care, University of Oxford

References

1. Piccirillo F, Liporace P, Nusca A et al. Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality‑a comprehensive review. J Cardiovasc Dev Dis 2023;10:236.
2. Kolkhof P, Jaisser F, Kim S-Y et al. Steroidal and novel non‑steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. In Bauersachs J et al (eds): Heart failure. Springer International Publishing, Cham, Switzerland, 2017:271–305.
3. Spironolactone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/12015/smpc#gref.
4. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8810/smpc.